Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: MSI-1436; Produlestan; Trodulamine

Latest Information Update: 29 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genaera Corporation
  • Developer DepYmed; Genaera Corporation; North Shore-Long Island Jewish Health System
  • Class Anorectics; Antihyperglycaemics; Antivirals; Biogenic amines; Cholestanes; Obesity therapies; Polyamines
  • Mechanism of Action Adrenergic uptake inhibitors; Apoptosis stimulants; Dopamine uptake inhibitors; Neuropeptide Y modulators; Protein-tyrosine-phosphatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Breast cancer
  • Discontinued Diabetes mellitus; HIV infections; Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 14 May 2018 DepYmed terminates a phase I trial in Breast cancer (Metastatic disease, Second-line therapy or greater) in USA due to lack of interest by sponsor (IV) (NCT02524951)
  • 15 Aug 2017 DepYmed suspends patient enrolment in a phase I trial in Breast cancer (Metastatic disease, Second-line therapy or greater) in USA due to pending revision of treatment schedule (IV) (NCT02524951)
  • 01 Apr 2016 Phase-I clinical trials in Breast cancer (Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT02524951)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top